Key result
Neuroinflammation molecular imaging biomarkers may help guide patient-specific immunomodulatory stroke therapies.
Answers are grounded in this paper and cite their sources.
Modulation of the inflammatory microenvironment after stroke opens a new avenue for the development of novel neurorestorative therapies in stroke. Understanding the spatio-temporal profile of (neuro-)inflammatory imaging biomarkers in detail thereby represents a crucial factor in the development and application of immunomodulatory therapies. The early integration of quantitative molecular imaging biomarkers in stroke drug development may provide key information about (i) early diagnosis and follow-up, (ii) spatio-temporal drug-target engagement (pharmacodynamic biomarker), (iii) differentiation of responders and non-responders in the patient cohort (inclusion/exclusion criteria; predictive biomarkers), and (iv) the mechanism of action. The use of targeted imaging biomarkers for may thus allow clinicians to decipher the profile of patient-specific inflammatory activity and the development of patient-tailored strategies for immunomodulatory and neuro-restorative therapies in stroke. Here, we highlight the recent developments in preclinical and clinical molecular imaging biomarkers of neuroinflammation (endothelial markers, microglia, MMPs, cell labeling, future developments) in stroke and outline how imaging biomarkers can be used in overcoming current translational roadblocks and attrition in order to advance new immunomodulatory compounds within the clinical pipeline.
No takes yet. Share an insight, caveat, or question.
Zinnhardt et al. (2018) conducted a review in Stroke. Molecular imaging biomarkers of neuroinflammation was evaluated. Molecular imaging biomarkers of neuroinflammation may help decipher patient-specific inflammatory activity and advance immunomodulatory stroke therapies into the clinical pipeline.
Synapse has enriched 10 related papers. Consider them for comparative context: